New drug combo tested for tough cancers
NCT ID NCT07215637
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 33 times
Summary
This study is for people with advanced solid tumors that have not responded to standard treatments. It tests a new drug called CKD-512, given alone or with another drug (pembrolizumab), to find safe doses and see how the body handles it. The goal is to control the disease, not cure it, and participants will be closely monitored for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.